Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies / Edition 1

by Peter Grunwald

Overview

This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

Product Details

ISBN-13:	9789814877138
Publisher:	Jenny Stanford Publishing
Publication date:	11/02/2020
Series:	Jenny Stanford Series on Biocatalysis
Pages:	478
Product dimensions:	6.00(w) x 9.00(h) x (d)

About the Author

Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.

Table of Contents

Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes. Phosphodiesterases. Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency. Advancing Phospholipase D Enzymes as Diverse Drug Targets. IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives. Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies. Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer. β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors. Non-Vitamin K Oral Anticoagulants (NOACs): New Options. Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease. Lysosomal Storage Disorders and Enzyme Replacement Therapy.

 

Editorial Reviews

Reviewer: Marc A Ilies, PhD (Temple University School of Pharmacy)
Description: This book covers the area of biocatalysis, with a focus on chemoenzymatic synthesis of various active pharmaceutical ingredients (APIs).
Purpose: The purpose is to highlight the application of biocatalysis in the synthesis of various drugs. The subject is in need of a comprehensive update. The book succeeds in emphasizing the excellent chemo-, regio-, and enantioselectivity of biocatalysts (natural and synthetic enzymes) in the synthesis of various classes of drugs.
Audience: The book is written for chemists, biochemists, biotechnologists, and pharmaceutical scientists (beginners and experts) interested in the use of enzymes in the synthesis of drugs. The author assembled an international team of experts who cover in detail, with ample examples, the use of biocatalysis for API synthesis and the advantages and limitations.
Features: The 21 chapters provide a comprehensive overview of the use of enzymes in the biosynthesis of drugs, presenting the different classes of biocatalysts (enzymes), their general properties, catalytic mechanisms and enzyme kinetics, and different classes of inhibitors available for each enzyme type (transaminases, hydrolases, lyases, oxidoreductases, etc.). Several chapters detail the use of these classes of enzymes in the biosynthesis of novel antibiotics, amino acid derivatives, antidiabetic drugs, antimalarial drugs, isoprenoids, various antioxidants, xanthones, etc. Comprehensive tables and figures (some in color) enrich and support the text. The use of enzymes for biosynthesis of enantiomeric pure drugs, either de novo or through resolution of racemic drug mixtures is particularly interesting, as are the future strategies for commercial biocatalysis that are presented.
Assessment: This is a valuable addition to the area of synthesis of biomolecules and drugs, highlighting the advantages and limitations of enzymes in a comprehensive analysis. It has the potential to become a classic in the area of biocatalysis for drug synthesis.

Doody's Review Service